Literature DB >> 21455745

Reduced hydrophobicity of the colonic mucosal surface in ulcerative colitis as a hint at a physicochemical barrier defect.

Annika Braun1, Ulrike Schönfeld, Thilo Welsch, Martina Kadmon, Benjamin Funke, Daniel Gotthardt, Alexandra Zahn, Frank Autschbach, Peter Kienle, Michael Zharnikov, Michael Grunze, Wolfgang Stremmel, Robert Ehehalt.   

Abstract

PURPOSE: There is increasing evidence that a defect of the gastrointestinal mucosal barrier is important for the development of inflammatory bowel diseases (IBD). The hydrophobicity of the colonic mucosal surface is a measure of its resistance to luminal antigens, e.g. of bacterial origin. Therefore, the purpose of this study was to determine this parameter in patients suffering from IBD.
METHODS: Nineteen patients with ulcerative colitis (UC), ten patients with Crohn's disease (CD) and 20 controls were examined. All underwent colonic surgery at the University Hospital Heidelberg. Clinical disease activity was determined. From every subject, colonic tissue specimens were obtained, and hydrophobicity of the mucosal surface was determined with a goniometer by multiple plateau contact angle measurements. Histological evaluation of disease activity was performed in directly adjacent tissue specimens.
RESULTS: Hydrophobicity of the colonic mucosal surface, expressed as plateau contact angles, was significantly reduced in patients with UC (mean ± SEM, 47.8° ± 3.4°) compared to those with CD (72.0° ± 5.2°) and controls (72.5° ± 5.6°; over-all P = 0.0004; UC versus controls, P < 0.001; UC versus CD, P < 0.05; CD versus controls, P > 0.05). Between mucosal hydrophobicity and clinical disease activity, as well as mucosal hydrophobicity and histological disease activity, no significant correlation was found.
CONCLUSIONS: The results suggest a defective physicochemical barrier as an essential factor in the pathogenesis of UC, but not CD. The fact that no correlation was found between mucosal hydrophobicity and disease activity may indicate that the loss of mucosal hydrophobicity in UC is not exclusively a secondary effect due to inflammation.

Entities:  

Mesh:

Year:  2011        PMID: 21455745     DOI: 10.1007/s00384-011-1190-z

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  33 in total

1.  Hydrophobicity of mucosal surface and its relationship to gut barrier function.

Authors:  Xiaofa Qin; Francis J Caputo; Da-Zhong Xu; Edwin A Deitch
Journal:  Shock       Date:  2008-03       Impact factor: 3.454

2.  Measurement of the surface hydrophobicity of human gastrointestinal mucosa.

Authors:  R T Spychal; J M Marrero; S H Saverymuttu; T C Northfield
Journal:  Gastroenterology       Date:  1989-07       Impact factor: 22.682

3.  Polyethylene glycol enhances colonic barrier function and ameliorates experimental colitis in rats.

Authors:  Sebastián Videla; Aurelia Lugea; Jaime Vilaseca; Francisco Guarner; Francesc Treserra; Antonio Salas; Ernesto Crespo; Carlos Medina; Juan R Malagelada
Journal:  Int J Colorectal Dis       Date:  2006-10-24       Impact factor: 2.571

4.  Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis.

Authors:  W Stremmel; U Merle; A Zahn; F Autschbach; U Hinz; R Ehehalt
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

5.  Mucosal flora in inflammatory bowel disease.

Authors:  Alexander Swidsinski; Axel Ladhoff; Annelie Pernthaler; Sonja Swidsinski; Vera Loening-Baucke; Marianne Ortner; Jutta Weber; Uwe Hoffmann; Stefan Schreiber; Manfred Dietel; Herbert Lochs
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

6.  Surface hydrophobicity of the rat colonic mucosa is a defensive barrier against macromolecules and toxins.

Authors:  A Lugea; A Salas; J Casalot; F Guarner; J R Malagelada
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

7.  Gastric mucosal hydrophobicity in duodenal ulceration: role of Helicobacter pylori infection density and mucus lipids.

Authors:  M Asante; H Ahmed; P Patel; T Davis; C Finlayson; M Mendall; T Northfield
Journal:  Gastroenterology       Date:  1997-08       Impact factor: 22.682

8.  Age and Helicobacter pylori decrease gastric mucosal surface hydrophobicity independently.

Authors:  A Hackelsberger; U Platzer; M Nilius; V Schultze; T Günther; J E Dominguez-Muñoz; P Malfertheiner
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

9.  Luminal surface hydrophobicity of canine gastric mucosa is dependent on a surface mucous gel.

Authors:  P J Goddard; Y C Kao; L M Lichtenberger
Journal:  Gastroenterology       Date:  1990-02       Impact factor: 22.682

10.  Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial.

Authors:  Wolfgang Stremmel; Robert Ehehalt; Frank Autschbach; Max Karner
Journal:  Ann Intern Med       Date:  2007-11-06       Impact factor: 25.391

View more
  7 in total

1.  In vivo analysis of mucosal lipids reveals histological disease activity in ulcerative colitis using endoscope-coupled Raman spectroscopy.

Authors:  Hao Ding; Andrew W Dupont; Shashideep Singhal; Larry D Scott; Sushovan Guha; Mamoun Younes; Xiaohong Bi
Journal:  Biomed Opt Express       Date:  2017-06-23       Impact factor: 3.732

2.  Milk Exosomes Prevent Intestinal Inflammation in a Genetic Mouse Model of Ulcerative Colitis: A Pilot Experiment.

Authors:  Wolfgang Stremmel; Ralf Weiskirchen; Bodo C Melnik
Journal:  Inflamm Intest Dis       Date:  2020-05-20

3.  The Detergent Effect of Mesalazine Interferes with Phosphatidylcholine Binding to Mucin 2.

Authors:  Wolfgang Stremmel; Simone Staffer; Sven Gehrke
Journal:  Inflamm Intest Dis       Date:  2018-10-18

4.  Phospholipase A2 of Microbiota as Pathogenetic Determinant to Induce Inflammatory States in Ulcerative Colitis: Therapeutic Implications of Phospholipase A2 Inhibitors.

Authors:  Wolfgang Stremmel; Simone Staffer; Nicole Stuhrmann; Hongying Gan-Schreier; Annika Gauss; Nina Burger; Daniel Hornuss
Journal:  Inflamm Intest Dis       Date:  2018-03-06

5.  First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses.

Authors:  Max Karner; Andreas Kocjan; Juergen Stein; Stefan Schreiber; Georg von Boyen; Peter Uebel; Carsten Schmidt; Limas Kupcinskas; Ion Dina; Frank Zuelch; Gerhard Keilhauer; Wolfgang Stremmel
Journal:  Am J Gastroenterol       Date:  2014-05-06       Impact factor: 10.864

6.  Genetic Mouse Models with Intestinal-Specific Tight Junction Deletion Resemble an Ulcerative Colitis Phenotype.

Authors:  Wolfgang Stremmel; Simone Staffer; Mathias Jochen Schneider; Hongying Gan-Schreier; Andreas Wannhoff; Nicole Stuhrmann; Annika Gauss; Hartwig Wolburg; Anne Mahringer; Alexander Swidsinski; Thomas Efferth
Journal:  J Crohns Colitis       Date:  2017-10-01       Impact factor: 9.071

7.  Phosphatidylcholine Passes by Paracellular Transport to the Apical Side of the Polarized Biliary Tumor Cell Line Mz-ChA-1.

Authors:  Wolfgang Stremmel; Simone Staffer; Ralf Weiskirchen
Journal:  Int J Mol Sci       Date:  2019-08-19       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.